Granted Patent
B2
US 12,410,256 · App. 18/304,136 · Granted Sep 9, 2025
Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseases
Inventors:
Lynn Dorothy Poulton (Macquarie Park, AU); Adam Clarke (Five Dock, AU); Andrew James Pow (Pascoe Vale, AU); Debra Tamvakis (Camberwell, AU); George Kopsidas (Preston, AU); Anthony Gerard Doyle (Drummoyne, AU); Philip Anthony Jennings (Warrawee, AU); Matthew Pollard (Dural, AU)
Assignee:
Cephalon LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.
Claims (19)
1. A method for treating a disease or disorder selected from inflammatory bowel disease or irritable bowel syndrome, comprising administering to a subject in need thereof a recombinant antibody that binds to TNF-like ligand 1A (TL1A), wherein the antibody comprises a heavy chain variable region CDR1 comprising amino acids 31 to 35 of SEQ ID NO: 186, a heavy chain variable region CDR2 comprising amino acids 50 to 66 of SEQ ID NO: 186, a heavy chain variable region CDR3 comprising amino acids 99 to 108 of SEQ ID NO: 186, a light chain variable region CDR1 comprising amino acids 23 to 36 of SEQ ID NO: 199, a light chain variable region CDR2 comprising amino acids 52 to 58 of SEQ ID NO: 199, and a light chain variable region CDR3 comprising amino acids 91 to 100 of SEQ ID NO: 199.
2. The method according to claim 1 , wherein the recombinant antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 186.
3. The method according to claim 1 , wherein the recombinant antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 199.
4. The method according to claim 1 , wherein the recombinant antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 186 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 199.
5. The method according to claim 1 , wherein the recombinant antibody comprises a human IgG1 heavy chain constant region.
6. The method according to claim 1 , wherein the recombinant antibody comprises a human light chain lambda constant region.
7. The method according to claim 1 , wherein the recombinant antibody comprises a human IgG1 heavy chain constant region and a human light chain lambda constant region.
8. The method according to claim 1 , wherein the disease or disorder is inflammatory bowel disease.
9. The method according to claim 8 , wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis.
10. The method according to claim 8 , wherein the inflammatory bowel disease is Crohn's disease.
11. The method according to claim 1 , wherein the recombinant antibody is capable of inhibiting the interaction of TL1A with the death receptor 3 (DR3).
12. The method according to claim 1 , wherein the recombinant antibody is capable of inhibiting the interaction of TL1A with the death receptor 3 (DR3) and is not capable of inhibiting the interaction of TL1A with the decoy receptor 3 (DcR3).
13. A method for treating a lung disease or disorder, comprising administering to a subject in need thereof a recombinant antibody thereof that binds to TNF-like ligand 1A (TL1A), wherein the antibody comprises a heavy chain variable region CDR1 comprising amino acids 31 to 35 of SEQ ID NO: 186, a heavy chain variable region CDR2 comprising amino acids 50 to 66 of SEQ ID NO: 186, a heavy chain variable region CDR3 comprising amino acids 99 to 108 of SEQ ID NO: 186, a light chain variable region CDR1 comprising amino acids 23 to 36 of SEQ ID NO: 199, a light chain variable region CDR2 comprising amino acids 52 to 58 of SEQ ID NO: 199, and a light chain variable region CDR3 comprising amino acids 91 to 100 of SEQ ID NO: 199, wherein the lung disease or disorder is allergic lung inflammation, asthma, chronic obstructive pulmonary disease (COPD), or pulmonary fibrosis.
14. The method according to claim 13 , wherein the recombinant antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 186.
15. The method according to claim 13 , wherein the recombinant antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 199.
16. The method according to claim 13 , wherein the recombinant antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 186 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 199.
17. The method according to claim 13 , wherein the recombinant antibody comprises a human IgG1 heavy chain constant region and a human light chain lambda constant region.
18. The method according to claim 13 , wherein the antibody is capable of inhibiting the interaction of TL1A with the death receptor 3 (DR3).
19. The method according to claim 13 , wherein the recombinant antibody is capable of inhibiting the interaction of TL1A with the death receptor 3 (DR3) and is not capable of inhibiting the interaction of TL1A with the decoy receptor 3 (DcR3).
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 14, 2025
From: POULTON, LYNN DOROTHY; CLARKE, ADAM; POW, ANDREW JAMES; TAMVAKIS, DEBRA; KOPSIDAS, GEORGE; JENNINGS, PHILIP ANTHONY; POLLARD, MATTHEW; DOYLE, ANTHONY GERARD
To: TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
Reel/Frame 071107/0662 →
Priority Claims (1)
AU 2011904042
· Sep 30, 2011
· national
Continuity (6)
Continuation
PCTAU2012001161
· Sep 28, 2012
Provisional Application
61541590
· Sep 30, 2011
References Cited (181)
US 7597886B2
· Yu et al.
· 2009
[cited by applicant]
US 7820798B2
· Yu et al.
· 2010
[cited by applicant]
US 8263743B2
· Smith et al.
· 2012
[cited by applicant]
US 8642741B2
· Classon et al.
· 2014
[cited by applicant]
US 8728482B2
· Smith et al.
· 2014
[cited by applicant]
US 9017679B2
· Podack et al.
· 2015
[cited by applicant]
US 9068003B2
· Siegel et al.
· 2015
[cited by applicant]
US 9290576B2
· Attinger et al.
· 2016
[cited by applicant]
US 9416185B2
· Smith et al.
· 2016
[cited by applicant]
US 9556277B2
· Classon et al.
· 2017
[cited by applicant]
US 9683998B2
· Arch et al.
· 2017
[cited by applicant]
US 20100190162A1
· Rotter
· 2010
[cited by examiner]
US 20110217310A1
· Siegel et al.
· 2011
[cited by applicant]
US 20120328559A1
· Podack et al.
· 2012
[cited by applicant]
US 20140255302A1
· Poulton et al.
· 2014
[cited by applicant]
WO 2005018571A2
· 2005
[cited by applicant]
WO 2005092927A1
· 2005
[cited by applicant]
WO 2006127900A2
· 2006
[cited by applicant]
WO 2007076465A2
· 2007
[cited by applicant]
WO 2008106451A2
· 2008
[cited by applicant]
WO 2009052512A2
· 2009
[cited by applicant]
WO 2009064854A2
· 2009
[cited by applicant]
WO 2010118210A1
· 2010
[cited by applicant]
WO 2011080314A2
· 2011
[cited by applicant]
WO 2012064682A1
· 2012
[cited by applicant]
WO 2012161856A1
· 2012
[cited by applicant]
WO 2012174338A2
· 2012
[cited by applicant]
WO 2013044298A1
· 2013
[cited by applicant]
WO 2014106602A1
· 2014
[cited by applicant]
WO 2014160883A1
· 2014
[cited by applicant]
WO 2014186665A2
· 2014
[cited by applicant]
WO 2014186750A2
· 2014
[cited by applicant]
WO 2015010108A1
· 2015
[cited by applicant]
WO 2015035261A1
· 2015
[cited by applicant]
WO 2015073580A1
· 2015
[cited by applicant]
WO 2016186972A1
· 2016
[cited by applicant]
WO 2017035017A1
· 2017
[cited by applicant]
WO 2017077715A1
· 2017
[cited by applicant]
WO 2017106383A1
· 2017
[cited by applicant]
WO 2017161342A1
· 2017
[cited by applicant]
WO 2017214547A1
· 2017
[cited by applicant]
WO 2018081074A1
· 2018
[cited by applicant]
WO 2018195328A1
· 2018
[cited by applicant]
WO 2019212899A1
· 2019
[cited by applicant]
WO 2020113116A1
· 2020
[cited by applicant]
WO 2020232125A1
· 2020
[cited by applicant]
WO 2021081365A1
· 2021
[cited by applicant]
WO 2021108694A1
· 2021
[cited by applicant]
WO 2021147548A1
· 2021
[cited by applicant]
WO 2021247770A1
· 2021
[cited by applicant]
WO 2021260577A2
· 2021
[cited by applicant]
Hsu et al., The tale of TL1A in inflammation, Mucosal Immunol. vol. 4, Issue 4p. 368-370Jul. 2011.
[cited by examiner]
Abdel-Razzak, Z., et al., “Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture,” Molecular Pharmacology, vol. 44, No. 4, pp. 707-715 (1993).
[cited by applicant]
Agoram, B., “Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics,” British Journal of Clinical Pharmacology, vol. 67, No. 2, pp. 153-160 (2008).
[cited by applicant]
Aiba, Y., et al., “The Role of TL1A and DR3 in Autoimmune and Inflammatory Diseases,” Mediators of Inflammation, vol. 2013, article 258164, pp. 1-9 (2013).
[cited by applicant]
Aiba, Y., et al., “Systemic and local expression levels of TNF-like ligand 1A and its decoy receptor 3 are increased in primary biliary cirrhosis,” Liver International, vol. 34, No. 5, pp. 679-688 (2014).
[cited by applicant]
Baker, D., et al., “Evaluation of IgE Antibodies to Omalizumab (Xolair®) and Their Potential Correlation to Anaphylaxis,” AAPS Journal, vol. 18, No. 1, pp. 115-123 (2016).
[cited by applicant]
Balyan, R., et al., “P633 First-in-Human Pharmacokinetic and Safety Study of an Anti-TL1A Antibody, TEV-48574, in Healthy Volunteers and Asthma Patients,” Journal of Crohn's and Colitis, vol. 18, Issue Supplement_1, pp.…
[cited by applicant]
Bamias, G., et al., “High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis,” Clinical Immunology, vol. 137, No. 2, pp. 242-249 (2010).
[cited by applicant]
Bamias, G., et al., “Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis,” Clinical Immunology, vol. 129, No. 2, pp. 249-255 (2008).
[cited by applicant]
Bamias, G., et al., “Differential expression of the TL1A/DcR3 system of TNF/TNFR-like proteins in large vs. small intestinal Crohn's disease,” Digestive and Liver Disease, vol. 44, No. 1, pp. 30-36 (2011).
[cited by applicant]
Bamias, G., et al., “Expression, Localization, and Functional Activity of TL1A, a novel Th1-Polarizing Cytokine in Inflammatory Bowel Disease,” Journal of Immunology, vol. 171, No. 9, pp. 4868-4874 (2003).
[cited by applicant]
Bamias, G., et al., “Role of TL1A and its receptor DR3 in two models of chronic murine ileitis,” PNAS, vol. 103, No. 22, pp. 8441-8446 (2006).
[cited by applicant]
Bamias, G., et al., “Upregulation and nuclear localization of TNF-like Cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions,” Experimental Dermatology, vol. 20, pp. 725-731 (2011).
[cited by applicant]
Banfield, C., et al., “First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects,” British Journal of Clinical…
[cited by applicant]
Barrett, R., et al., “Abstract 925: In Vivo Constitutive Expression of an IBD Associated Gene TNFSF15 Causes Severe Inflammation and Induces Fibrostenotic Disease in 2 Murine Models of Chronic Colitis,” AGA Abstracts, p…
[cited by applicant]
Bayry, J., “TL1A in the inflammatory network in autoimmune diseases,” Nature Reviews, vol. 6, pp. 67-68 (2010).
[cited by applicant]
Bull, M., et al., “The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis,” Journal of Experimental Medicine, vol. 205, No. 11, pp. 2457-2464 (2008).
[cited by applicant]
Chang, K., et al., “Affinity Maturation of an Epidermal Growth Factor Receptor Targeting Human Monoclonal Antibody ER414 by CDR Mutation,” Immune Network, vol. 12, No. 4, pp. 155-164 (2012).
[cited by applicant]
Chen, C., et al., “Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations,” The EMBO Journal, vol. 14, No. 12, pp. 2784-2794 (1995).
[cited by applicant]
Clarke, A., et al., “An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease,” mABS, vol. 10, No. 4, pp. 664-677 (2018).
[cited by applicant]
Connelly, T., et al., “The TNFSF15 Gene Single Nucleotide Polymorphism rs7848647 is Associated with Surgical Diverticulitis,” Annals of Surgery, vol. 259, No. 6, pp. 1132-1137 (2014).
[cited by applicant]
Corren, J., “New Targeted Therapies for Uncontrolled Asthma,” Journal of Allergy and Clinical Immunology: In Practice, vol. 7, No. 5, pp. 1394-1403 (2019).
[cited by applicant]
Czogalla, B., et al., “A meta-analysis of immunogenetic Case-Control Association Studies in irritable bowel syndrome,” Neurogastroenterology & Motility, vol. 27, No. 5, pp. 717-727 (2015).
[cited by applicant]
Danese, S., et al., “Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study,” Clinical Gastroenterology and Hepatology, vol. 19, pp. 2324-2332 (2021).
[cited by applicant]
Daugherty, P., et al., “Quantitative analysis of the effect of the mutation frequency on the affinity maturation of single chain Fv antibodies,” PNAS, vol. 97, No. 5, pp. 2029-2034 (2000).
[cited by applicant]
Diamant, Z., et al., “Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics,” Clinical & Experimental Allergy, vol. 44, No. 8, pp. 1044-1052 (2014).
[cited by applicant]
Endo, K., et al., “TL1A (TNFSF15) genotype affects the long-term therapeutic outcomes of anti-TNFα antibodies for Crohn's disease patients,” Journal of Gastroenterology and Hepatology, vol. 4, pp. 1108-1113 (2020).
[cited by applicant]
Facco, M., et al., “TL1A/DR3 axis involvement in the inflammatory cytokine network during pulmonary sarcoidosis,” Clinical and Molecular Allergy, vol. 13, No. 16, pp. 1-11 (2015).
[cited by applicant]
Fahy, J., et al., “Type 2 inflammation in asthma—present in most, absent in many,” Nature Reviews Immunology, vol. 15, No. 1. pp. 57-65, (2015).
[cited by applicant]
Fang, L., et al., “Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation,” Journal of Experimental Medicine, vol. 205, No. 5, pp. 1037-1048 (2008).
[cited by applicant]
Franciosi, L., et al., “Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials,” Lan…
[cited by applicant]
Galant, S., “The Evaluable Subject,” Annals of Allergy, Asthma, & Immunology, vol. 79, pp. 173-175 (1997).
[cited by applicant]
Girish, S., et al., “AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical development,” AAPS Journal, vol. 13, No. 3, pp. 405-416 (2011).
[cited by applicant]
Haritunians, T., et al., “Genetic predictors of medically refractory ulcerative colitis,” Inflammatory Bowel Disease, vol. 16, No. 11, pp. 1830-1840 (2010).
[cited by applicant]
Hassan-Zahraee, M., et al., “Abstract P446: Transcriptional and microbial biomarkers of response to anti-TL1A therapy in ulcerative colitis: the Phase 2a Tuscany study,” Abstracts of the 15th Congress of ECCOL, pp. S401…
[cited by applicant]
Herro, R., et al., “TL1A Promotes Lung Tissue Fibrosis and Airway Remodeling,” Journal of Immunology, vol. 205, No. 9, pp. 2414-2422 (2020).
[cited by applicant]
Hirano, A., et al., “Association study of 71 European Crohn's disease susceptibility loci in a Japanese population,” Inflammatory Bowel Disease, vol. 19, No. 3, pp. 526-533 (2013).
[cited by applicant]
Huang, S., et al., “Therapeutic protein-drug interactions and implications for drug development,” Clinical Pharmacology and Therapeutics, vol. 87, pp. 497-503 (2010).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/AU2011/001662, by Anita Premkumar, mailed on Feb. 20, 2012, 8 pages.
[cited by applicant]
International Search Report and written Opinion for International Application No. PCT/US2016/052040, by Rene Wagner, mailed on Dec. 5, 2016, 12 pages.
[cited by applicant]
International Search Report and Written Opinion from International Application No. PCT/AU2012/001161 by Margaret Chang, mailed Dec. 10, 2012 (10 pages).
[cited by applicant]
Jia, Y., et al., “IL-13+ Type 2 innate lymphoid cells correlate with asthma control status and treatment response,” American Journal of Respiratory Cell and Molecular Biology, vol. 55, No. 5, pp. 675-683 (2016).
[cited by applicant]
Jin, T., et al., “X-ray crystal structure of TNF ligand family member TL1A at 2.1A,” Biochemical & Biophysical Research Communications, vol. 364, pp. 1-6 (2007).
[cited by applicant]
Jones, G., et al., “Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation,” The FASEB Journal, vol. 25, No. 1, pp. 409-419 (2011).
[cited by applicant]
Jover, R., et al., “Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved,” FASEB Journal, vol. 16, No. 13, pp. 1799-1801 (2002).
[cited by applicant]
Kakuta, Y., et al., “TNFSF15 transcripts from risk haplotype for Crohn's disease are overexpressed in stimulated T cells,” Human Molecular Genetics, vol. 18, No. 6, pp. 1089-1098 (2009).
[cited by applicant]
Kamada, N., et al., “TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease,” Inflammatory Bowel Disease, vol. 16, No. 4, pp. 568-575…
[cited by applicant]
Kayamuro, H., et al., “TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant,” Biochemical and Biophysical Research Communications, vol. 384, No. 3, pp. 296-300 (2009).
[cited by applicant]
Kim, H., et al., “Omalizumab: Practical considerations regarding the risk of anaphylaxis,” Allergy, Asthma & Clinical Immunology, vol. 6, No. 1, p. 32 (2010).
[cited by applicant]
Konsta, M., et al., “Increased levels of soluble TNF-like cytokine 1A in ankylosing spondylitis,” Rheumatology (Oxford), vol. 52, No. 3, pp. 448-451 (2013).
[cited by applicant]
Lamminmaki, U., et al., “Crystal structure of a recombinant anti-estradiol Fab fragment in complex with the 17beta-estradiol,” Journal of Biological Chemistry, vol. 276, No. 39, pp. 36687-36694 (2001).
[cited by applicant]
Leckie, M. et al., “Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response,” Lancet, vol. 356, pp. 2144-2148 (2000).
[cited by applicant]
Liu, J., et al., “Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations,” Nature Genetics, vol. 47, No. 9, pp. 979-986 (2015).
[cited by applicant]
Ma, L., et al., “Case fatality and population mortality associated with anaphylaxis in the United States,” Journal of Allergy & Clinical Immunology, vol. 133, No. 4, pp. 1075-1083 (2014).
[cited by applicant]
MacCallum, R., et al., “Antibody-antigen interactions: contact analysis and binding site topography,” Journal of Molecular Biology, vol. 262, pp. 732-745, (1996).
[cited by applicant]
Meylan, F., et al., “The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation,” Mucosal Immunology, vol. 4, No. 2, pp. 172-185 (2011).
[cited by applicant]
Meylan, F., et al., “The TNF-family cytokine TL1A promotes allergic immunopathology through group 2 innate lymphoid cells,” Mucosal Immunology, vol. 7, No. 4, pp. 958-968 (2014).
[cited by applicant]
Meylan, F., et al., “The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases,” Immunity, vol. 29, No. 1, pp. 79-89 (2008).
[cited by applicant]
Meylan, F., et al., “TNF superfamily cytokines in the promotion of Th9 differentiation and immunopathology,” Seminars in Immunopathology, vol. 39, No. 1, pp. 21-22 (2017).
[cited by applicant]
Michelsen, K., et al., “IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein,” PLoS One, vol. 4, No. 3, p. e4719 (2009).
[cited by applicant]
Migone, T., et al., “TL1A is a TNF-like Ligand for DR3 and TR6/DcR3 and Functions as a T Cell Costimulator,” Immunity, vol. 16, pp. 479-492 (2002).
[cited by applicant]
Mjosberg, J., et al., “Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161,” Nature Immunology, vol. 12, No. 11, pp. 1055-1062 (2011).
[cited by applicant]
Moffatt, M., et al., “A large-scale, consortium-based genomewide association study of asthma,” New England Journal of Medicine, vol. 363, No. 13, pp. 1211-1221 (2010).
[cited by applicant]
Muntané-Relat, J., et al., “Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture,” Hepatology, vol. 22, No. 4, pt 1, pp. 1143-1153 (1995).
[cited by applicant]
Neill, D., et al., “Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity,” Nature, vol. 464, No. 7293, pp. 1367-1370 (2010).
[cited by applicant]
Office Action mailed Mar. 23, 2018, by Claire M. Kaufman, in U.S. Appl. No. 15/267,213, 8 pages.
[cited by applicant]
Papadakis, K., et al., “TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells,” Journal of Immunology, vol. 172, No. 11, pp. 7002-7007 (2004).
[cited by applicant]
Pappu, B., et al., “TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease,” Journal of Experimental Medicine, vol. 205, No. 5, pp. 1049-1062 (2008).
[cited by applicant]
Pedersen, A., et al., “Secretion, blood levels and cutaneous expression of TL1A in psoriasis patients,” APMIS, vol. 123, No. 7, pp. 547-555 (2015).
[cited by applicant]
Prehn, J., et al., “Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation,” Clinical Immunology, vol. 112, No. 1, pp. 66-77 (2004).
[cited by applicant]
Rajpal, A., et al., “A general method for greatly improving the affinity of antibodies by using combinatorial libraries,” PNAS, vol. 102, No. 24, pp. 8466-8471 (2005).
[cited by applicant]
Raphael, G., et al., “P1061 TEV-48574, an anti-TL1A antibody in development for use in IBD, is safe and well tolerated following 16 weeks of subcutaneous treatment in adults with severe uncontrolled T2-low/non T2 asthma…
[cited by applicant]
Reinisch, W., et al., “P998 Phase 2 basket design study evaluating the efficacy and safety of an anti-TL1A antibody (TEV-48574) in moderate to severe ulcerative colitis or Crohn's Disease (Relieve UCCD),” Journal of Cro…
[cited by applicant]
Richard, A., et al., “The TNF-family ligand TL1A and its receptor DR3 promote T cell-mediated allergic immunopathology by enhancing differentiation and pathogenicity of IL-9-producing T cells,” Journal of Immunology, vo…
[cited by applicant]
Sampson, H., et al., “Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium,” Journal…
[cited by applicant]
Schleich, F., et al., “Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR),” Respiratory Medicine, vol. 108, pp. 1723-1732 (2014).
[cited by applicant]
Screaton, G., et al., “LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing,” PNAS, vol. 94, No. 9, pp. 4615-4619 (1997).
[cited by applicant]
Sela-Culang, I., et al., “The structural basis of antibody-antigen recognition,” Frontiers in Immunology, vol. 4, No. 302, pp. 1-13 (2013).
[cited by applicant]
Shah, D., et al., “Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human,” Journal of Pharmacokinetics and Pharmacodynamics, vol. 39, N…
[cited by applicant]
Shah, R., et al., “ICH E14 Q&A(R2) document: commentary on the further updated recommendations on thorough QT studies,” British Journal of Clinical Pharmacology, vol. 79, No. 3, pp. 456-464 (2015).
[cited by applicant]
Sharma, V., et al., “To scale or not to scale: the principles of dose extrapolation,” British Journal of Pharmacology, vol. 157, No. 6, pp. 907-921 (2009).
[cited by applicant]
Shih, D., et al., “Abstract 357: Reversal of Murine Colitis and Fibrosis by Neutralizing TL1A Antibody: Potential Novel Therapy to Alter Natural History of Crohn's Disease,” AGA Abstracts, p. S-84 (2012).
[cited by applicant]
Shih, D., et al., “Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis,” Mucosal Immunology, vol. 7, No. 6, pp. 1492-1503 (2014).
[cited by applicant]
Singh, R., et al., “Death receptor 3 regulates distinct pathological attributes of acute versus chronic murine allergic lung inflammation,” Cellular Immunology, vol. 320, pp. 62-70 (2017).
[cited by applicant]
Soroosh, P.,et al., “Th9 and allergic disease,” Immunology, vol. 127, No. 4, pp. 450-458 (2009).
[cited by applicant]
Steidl, S., et al., “In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification,” Molecular Immunology, vol. 46, No. 1, pp. 135-144 (2008).
[cited by applicant]
Swan, C., et al., “Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα,” Gut, vol. 62, No. 7, pp. 985-994 (2013).
[cited by applicant]
Takedatsu, H., et al., “TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation,” Gastroenterology, vol. 135, No. 2, pp. 552-567 (2008).
[cited by applicant]
Thie, H., “Affinity Maturation by Random Mutagenesis and Phage Display,” Antibody Engineering, vol. 1, pp. 397-409 (2010).
[cited by applicant]
Thiebaut, R., et al., “TNFSF15 polymorphisms are associated with susceptibility to inflammatory bowel disease in a new European cohort,” American Journal of Gastroenterology, vol. 104, No. 2, pp. 384-391 (2009).
[cited by applicant]
Tranter, E., et al., “Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?,” British Journal of Clinical Pharmacology, vol. 76, No. 2, pp. 164-172 (2013).
[cited by applicant]
Valatas, V., et al., “TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity,” Frontiers in Immunology, vol. 10, No. 583, pp. 1-14 (2019).
[cited by applicant]
Van Rijt, L., et al., “Type 2 innate lymphoid cells: at the cross-roads in allergic asthma,” Seminars in Immunopathology, vol. 38, pp. 483-496 (2016).
[cited by applicant]
Vargas, H., et al., “Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics,” Journal of Pharmacology & Toxicology Methods, vol. 58, No. 2, pp. 72-76 (2008).
[cited by applicant]
Vugmeyster, Y., et al., “Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges,” World Journal of Biological Chemistry, vol. 3, No. 4, pp. 73-92 (2012).
[cited by applicant]
Wang, W., et al., “Monoclonal antibody pharmacokinetics and pharmacodynamics,” Clinical Pharmacology & Therapeutics, vol. 84, No. 5, pp. 548-558 (2008).
[cited by applicant]
Wen, L., et al., “TL1A-induced NF-KB activation and c-IAP2 production Prevent DR3-mediated apoptosis in TF-1 Cells,” Journal of Biological Chemistry, vol. 278, No. 40, pp. 39251-39258 (2003).
[cited by applicant]
Wenzel, S., et al., “Dupilumab in persistent asthma with elevated eosinophil levels,” New England Journal of Medicine, vol. 368, No. 26, pp. 2455-2466 (2013).
[cited by applicant]
Wolterink, R., et al., “Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma,” European Journal of Immunology, vol. 42, No. 5, pp. 1106-1116 (2012).
[cited by applicant]
Woodcock, A., et al., “Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial,” Ches…
[cited by applicant]
Xu, W., et al., “Elevated plasma levels of TL1A in newly diagnosed systemic lupus erythematosus patients,” Rheumatology International, vol. 35, No. 8, pp. 1435-1437 (2015).
[cited by applicant]
Xue, L., et al., “Evaluation of pre-existing antibody presence as a risk factor for posttreatment antidrug antibody induction: analysis of human clinical study data for multiple biotherapeutics,” AAPS Journal, vol. 15, …
[cited by applicant]
Yamazaki, K., et al., “Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease,” Human Molecular Genetics, vol. 14, No. 22, pp. 3499-3506 (2005).
[cited by applicant]
Yang, C., et al., “Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor D necrosis factor superfamily and exhibiting angiostatic action,” Cancer Research, vol. 64, pp. 1…
[cited by applicant]
Yang, W., et al. “CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range,” Journal of Molecular Biology, vol. 254, pp. 392-403 (1995).
[cited by applicant]
Yu, X., et al., “TNF superfamily member TL1A elicits type 2 innate lymphoid cells at mucosal barriers,” Mucosal Immunology, vol. 7, No. 3, pp. 730-740 (2014).
[cited by applicant]
Zhan, C., et al., “Biochemical and Structural Characterization of the Human TL1A Ectodomain,” Biochemistry, vol. 48, pp. 7636-7645 (2009).
[cited by applicant]
Zhan, C., et al., “Decoy strategies: The structure of TL1A:DcR3 complex,” Structure, vol. 19, No. 2, pp. 162-171 (2011).
[cited by applicant]
Zhang, J., et al., “Associations between TNFSF15 polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: A meta-analysis,” Autoimmunity, vol. 47, No. 8, pp. 512-518 (2014).
[cited by applicant]
Zhao, J., et al., “Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model,” Pharmaceutical Research, vol. 32, No. 10, pp. 3269-3281 (2015).
[cited by applicant]
Zhao, L., et al., “Clinical pharmacology considerations in biologics development,” Acta Pharmacologica Sinica, vol. 33, No. 11, pp. 1339-1347 (2012).
[cited by applicant]
Zheng, L., et al., “Abstract 735: Distinct Effects of IFN-γ and IL-17A on TL1AModulated Murine Regional Inflammation and Fibrosis,” AGA Abstracts, p. S-132 (2013).
[cited by applicant]
Zheng, L., et al., “Sustained Tl1a (Tnfsf15) Expression On Both Lymphoid And Myeloid Cells Leads To Mild Spontaneous Intestinal Inflammation And Fibrosis,” European Journal of Microbiologic Immunology, vol. 3, No. 1, pp…
[cited by applicant]
Zidek, Z., et al., “Current status and challenges of cytokine pharmacology,” British Journal of Pharmacology, vol. 157, No. 3, pp. 342-361 (2009).
[cited by applicant]
Zucchelli, M., et al., “Association of TNFSF15 polymorphism with irritable bowel syndrome,” Gut, vol. 60, No. 12, pp. 1671-1677 (2011).
[cited by applicant]
Balyan, R., et al., “First-in-Human Pharmacokinetic and Safety Study of an Anti-TL1A Antibody, TEV-48574, in Healthy Volunteers and Patients with Asthma,” American Gastroenterological Association Abstracts, vol. 166, No…
[cited by applicant]
Dotan, O., et al., “Population pharmacokinetic analysis of duvakitug (TEV-48574) in healthy participants and patients with asthma”, Poster Presentation: American Society for Clinical Pharmacology & Therapeutics Annual M…
[cited by applicant]